Fiche publication
Date publication
novembre 2021
Journal
Pharmaceutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MONASSIER Laurent
,
Dr BECKER Guillaume
Tous les auteurs :
Becker G, Da Silva S, Sabo AN, Antal MC, Kemmel V, Monassier L
Lien Pubmed
Résumé
Serotonin affects many functions in the body, both in the central nervous system (CNS) and the periphery. However, its effect on the blood-brain barrier (BBB) in separating these two worlds has been scarcely investigated. The aim of this work was to characterize the serotonin receptor 5-HT in the hCMEC/D3 cell line, in the rat and the human BBB. We also examined the effect of prucalopride, a 5-HT receptor agonist, on the permeability of the hCMEC/D3 in an in vitro model of BBB. We then confirmed our observations by in vivo experiments. In this work, we show that the 5-HT receptor is expressed by hCMEC/D3 cells and in the capillaries of rat and human brains. Prucalopride increases the BBB permeability by downregulating the expression of the tight junction protein, occludin. This effect is prevented by GR113808, a 5-HT receptor antagonist, and is mediated by the Src/ERK1/2 signaling pathway. The canonical G-protein-dependent pathway does not appear to be involved in this phenomenon. Finally, the administration of prucalopride increases the diffusion of Evans blue in the rat brain parenchyma, which is synonymous with BBB permeabilization. All these data indicate that the 5-HT receptor contributes to the regulation of BBB permeability.
Mots clés
5-HT4 receptor, blood–brain barrier permeability, hCMEC/D3, microvascular endothelial cells, prucalopride, serotonin
Référence
Pharmaceutics. 2021 11 3;13(11):
